This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Doctors on Tuesday got a more detailed idea of how the therapy works and who might be eligible to take it, as results from a late-stage trial were presented at ASH.
After an initial rejection in 2020 and a review delay earlier this year, BioMarin’s Roctavian has finally got the FDA go-ahead to introduce a genetherapy for a not-so-rare disorder.
David Davidson is leaving Bluebird bio after nearly a decade as the genetherapy developer's top doctor. His new home, Tessera, just raised $230 million to advance its "gene writing" research.
Uptake of Casgevy and Lyfgenia may be slow despite their dramatic benefit, physicians said, citing complexities in treatment, manufacturing and reimbursement.
Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the genetherapy’s risks against its benefit.
Then, months later, doctors delivered genetherapy directly to her brain. A rare genetic disorder kept her from even lifting her head. Her parents took turns holding her upright at night just so she could breathe comfortably and sleep. Read the rest…
AbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get its hands on a genetherapy for wet age-related macular degeneration (AMD) and other eye diseases. The post AbbVie spies potential in Regenxbio eye disease genetherapy appeared first on.
Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its genetherapy SRP-9001 for Duchenne muscular dystrophy (DMD) in the next few months, with a view to making it available in sometime around the middle of 2023.
Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based genetherapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
It’s been a big week for cell and genetherapy approvals in the US, including a much-awaited approval for one to treat hemophilia A, the most common form of hemophilia. BioMarin said the majority of patients who received Roctavian received corticosteroids to suppress the immune system for the genetherapy to be effective and safe.
As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their CRISPR-based gene-editing therapy Casgevy, one doctor who treats sickle cell disease patients is already | As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their world-first CRISPR-based genetherapy Casgevy, one doctor (..)
Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical genetherapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). As a topical treatment, it is also the first readily redosable genetherapy.
Scientists and doctors at University College London Great Ormond Street Institute of Child Health (UCL GOS ICH) and Great Ormond Street Hospital (GOSH) have given hope of a genetherapy cure to children with a rare degenerative brain disorder called Dopamine Transporter Deficiency Syndrome (DTDS).
In September 2021, GlobalData figures revealed there to be 1,320 industry-sponsored regenerative medicine and advanced therapy trials ongoing worldwide. Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications.
You know how to protect against COVID and flu so ask your pharmacist or doctor about scheduling an RSV vaccine, too.” The commercial talks about RSV being a “highly contagious virus” and that people 60 years of age and older have a higher risk of being hospitalized from RSV, making vaccination against the virus important.
In 1981, I got my doctorate degree in Clinical Pharmacology, but more importantly, my research was heavily involved in neonatal medicine, developing drugs there. That has to do a lot with the work in genetherapy and rare disease and the ultra-rare space because there are 7,000 rare diseases that have been identified.
They had been modified in a lab by adding a functional gene to compensate for a defective one. Conner’s doctors expect that this groundbreaking genetherapy, which costs a staggering $3 million a patient, will stave off a fatal degenerative brain disease and save his life.
Under the leadership of CEO Vas Narasimhan, who took over in 2018, the company has focused on using digital technology to engage with both patients and doctors. Marie-France Tschudin, president of Novartis’s pharmaceuticals business, said digital technology had helped to improve productivity and its interactions with doctors.
Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like genetherapy Zolgensma gathered pace. . Correcting for currency fluctuations, net sales were flat at $12.3
Whether catching up with relatives, attending a business meeting, or even visiting a doctor, it became commonplace to conduct this type of activity via a screen. According a Pew Research study, 81% of participants said they have used video calls to talk to others since the onset of the pandemic. Tapping into data.
Many are still predicting multibillion-dollar sales for the drug, albeit with a longer runway, despite reservations about its clinical efficacy among doctors and payers. Analysts meanwhile have suggested that Aduhelm may start to pick up momentum if that review is positive.
A doctor inserts the catheter through a small incision in a vein in the groin and guides it to the heart. The catheters tip is positioned at various locations within the heart, where the doctor uses a generator to deliver RF energy. Companion diagnostic for Pfizers hemophilia B genetherapy Beqvez (idanacogene elaparvovec-dzkt).
Roche’s Susvimo (ranibizumab sustained release formulation) follows a similar theme; patients who are implanted with Susvimo are expected to visit their doctor only twice a year to have the implant refilled so that the medicine can be delivered to their eyes continuously. The therapy received FDA approval in October last year.
I am in the Doctorate in Nursing Practice program at the University of California, San Francisco, and I’m really looking forward to, becoming the first person in my family on either side to achieve a doctorate degree. We started experimenting with different genetherapies and antisense therapies.
There are many aspects of oncology drug development that are driven by the unique nature of the treatments being developed and the needs of the patients, their caregivers and the doctors that treat them. Morrison remarked that the latest ESMO was unique in its broad discussion scope, touching on various innovative treatments.
Many of the small challenges that face individual doctors and patients in seeking to find a solution for a rare disease also contribute to the difficulty of researching and developing an effective treatment. Once diagnosed, only 5% of rare diseases actually have an effective treatment. The outlook for rare disease R&D. Work to be done.
FoCus investigator Prof Karl Heinz Weiss of Salem Medical Centre Heidelberg said the results “have the potential to reframe the way doctors can think about the disease given that current therapies focus on removing copper from the blood.”
.” At Novartis, she was involved with projects including multiple sclerosis therapy Kesimpta (ofatumumab), migraine therapy Aimovig (erenumab), and Parkinson’s disease, and the acquisition by Novartis of optogenetic genetherapy company Vedere Bio.
Especially if you move into things like genetherapies.”. With COVID-19 posing an added risk to people with CF, Vertex was “even more motivated” to secure its supply chain and access to drugs. Engaging with the health system as early as possible and working flexibly was key to the success, he adds. “It It has to be more collaborative.
Dr. Pirozzi received a Doctorate of Medicine from Università Campus Bio-Medico di Roma in Italy, a Doctorate of Philosophy in Immunology from Sapienza Università di Roma in Italy, a Post-Doctorate degree in Immunology from the Institut Pasteur in Paris, France, and business training at the London Business School, UK.
Across LabCorp , we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients. Through partnerships and internal innovation, LabCorp is utilising these advances in order to improve healthcare stakeholders’ experiences for better patient results.
This often puts patients in difficult situations where they are passed between doctors until a correct diagnosis is reached. There are 7,000 known rare diseases, most of which non-specialist healthcare professionals have never encountered before. The stakes are high when launching an orphan drug product, however.
And those doctors have been born with TikTok on the mind and they will not go with the communication from the previous millennium. Hutnik gave an example of her work with Spark Therapeutics to develop a product to teach haemophilia patients about genetherapy. The first Gen Z HCPs are reaching the practice.
Matt Fisher, MD qualified from Bristol Medical School in 2015 and worked as a doctor in general and emergency medicine for five years in the NHS. The research I have conducted so far covers a plethora of innovative therapeutic areas, from genetherapy to CRISPR technology and I look forward to diversifying this expertise at Velocity.”
The case may give doctors pause before prescribing the treatment in the future, some analysts wrote. A young man treated with Elevidys died of acute liver failure.
We started, you know, experimenting with different genetherapies and antisense therapies. Doctors actually like to write. Our foundation has, we have identified a lead genetherapy candidate. So when I began, you know, the FOXG1 Research Foundation with a group of parents, we really act like a mini biotech.
A very important question was raised by the webinar attendee of the diversity and inclusion of patients in clinical research, and Dr Hackett commented: “A lot of the work has been done in our Paediatric & Rare Disease network, as well as our Cell and GeneTherapy network, we are tackling the issue of diversity in data.
On the theme of continuing to advance and evolve meeting capabilities as well, Shawah noted that most doctors are not on LinkedIn, so it is difficult to be connected with reps. Veeva is equally ‘super excited’. Coming in April 2023, this will be part of the Engage license.
For example, a LinkedIn article on the future of genetherapy can position a brand as an authority in genetic medicine, attracting biotech investors, researchers, and prescribing physicians. Doctor-patient interviews on managing chronic conditions. Engage in LinkedIn groups to build relationships with physicians and researchers.
Novartis’ Zolgensma (onasemnogene abeparvovec) genetherapy has been making significant strides as of late, including dosing of the first Spinal Muscular Atrophy (SMA) patient with the treatment in the UK last week. Related: Is $2 Million Too Much For FDA-Approved SMA GeneTherapy? Zolgensma GeneTherapy: START Trial.
Patient advocates and doctors are anticipating an approval this month of a treatment they believe to be a breakthrough for a deadly disease. But it’s not clear how well the therapy really works, putting the FDA in a difficult position.
Dr. Philipson’s transition to the biotech sector began with a position at UK-based biotech Trizell, where his efforts culminated in a genetherapy FDA submission for bladder cancer. Philipson, underscoring a commitment that would shape his career’s trajectory.
This meeting will host a panel of rare disease patients, caregivers, and advocates to have a focused discussion on the emerging field of genetherapy (regulated at the FDA by OTP). At least some (if not all) of the panelists will have had experience participating in genetherapy trials.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content